查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1916852

腺病毒純化試劑盒市場按技術、規格、等級、應用和最終用戶分類－全球預測（2026-2032 年）

Adenovirus Purification Kit Market by Technology, Scale, Grade, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腺病毒純化試劑盒市場價值將達到 12.3 億美元，到 2026 年將成長至 13.4 億美元，到 2032 年將達到 23.4 億美元，複合年成長率為 9.63%。

主要市場統計數據
基準年 2025 12.3億美元
預計年份：2026年 13.4億美元
預測年份：2032年 23.4億美元
複合年成長率 (%) 9.63%

對影響腺病毒純化在研發和生產環境中優先事項的技術、法規和營運背景進行簡明扼要的概述

腺病毒純化是現代基因傳遞、疫苗研發和病毒學研究的關鍵步驟，需要嚴格控制其純度、效力和可擴展性。近年來，載體工程技術的進步、病毒載體在治療研發管線中應用的日益廣泛以及監管要求的不斷提高，使得純化成為一個日益重要的交叉環節，直接影響下游製程的效率和生產經濟性。本報告整合了技術發展、營運挑戰和相關人員的需求，清楚闡述了影響純化策略的策略要務。

技術融合、監管收緊和平台策略將如何重塑腺病毒純化實踐和商業性合作

由於技術進步的融合、監管要求的不斷變化以及研發人員策略重點的轉變，腺病毒純化領域正經歷著變革性的變化。例如，持續的製程強化推動了對單元操作的重新評估，並促使人們整合模組化解決方案，以在保持載體完整性的同時縮短保存時間。同時，自動化和封閉系統的興起正在重塑實驗室和生產設施在產能和污染控制之間取得平衡的方式，使得規模小規模的設施也能生產出穩定、高品質的產品。

評估2025年美國關稅對採購、採購策略和生產連續性的營運和策略影響

美國將於2025年對部分進口商品加徵關稅，這項政策對生物製程材料的採購、生產計畫以及整個全球供應鏈結構產生了連鎖反應。層析法樹脂、膜組件及相關耗材的採購決策已進行調整，以因應到岸成本和供應商經濟狀況的變化。為此，許多企業正在加快對替代供應商的區域資格認證，同時建立關鍵物料的庫存緩衝，以防止生產中斷。

將技術選擇、應用需求、最終用戶能力、規模考量和等級要求連結起來的實用細分分析，有助於最佳化策略和供應商選擇。

深入理解分離過程對於開發滿足不同使用者需求的純化方法和商業策略至關重要。從技術角度來看，層析法是核心，其中親和性和層析法、離子交換層析法和尺寸排除層析法各自發揮獨特的作用。同時，滲濾、微濾和超過濾等過濾技術可以補充濃縮和緩衝液交換。硫酸銨沉澱和聚乙二醇（PEG）沉澱等沉澱技術則在特定領域有廣泛的應用，尤其是在早期研發階段，這些階段對簡便性和成本效益要求較高。這些技術差異會影響解析度、可擴展性和與下游分析的兼容性等決策標準。

區域架構：識別美洲、歐洲、中東和非洲以及亞太地區的發展對採購選擇、監管協調和產能規劃的影響

區域趨勢對腺病毒純化生態系的採購、監管合規和產能發展都有深遠影響。在美洲，強大的生物製藥製造群支撐著廣泛的合約開發和生產活動，本地化的供應商網路和服務供應商能夠實現快速的製程轉移和規模化生產。這種集中化有利於合作開發模式的形成，但也導致對某些耗材和高性能材料的需求集中，這可能會在專案活動活性化期給供應鏈帶來壓力。

技術差異化、整合服務模式和策略夥伴關係關係如何影響腺病毒純化供應商之間的競爭和韌性

腺病毒純化領域的企業競爭格局取決於對差異化技術、垂直整合策略和服務型經營模式的投資。專注於高性能配體和膜創新的企業在產品品質和工藝經濟性方面脫穎而出，而強調自動化和封閉式系統平台的企業則在易用性和適用性可擴展性方面展開競爭。包括合約組織和專業製程開發團隊在內的服務供應商，透過提供整合開發、規模化和轉移能力，將自身定位為客戶團隊的延伸。

為決策者提供關於平衡煉油創新、供應鏈韌性和監管準備的實用策略和營運建議

為了保持競爭力並滿足不斷變化的客戶需求，產業領導者應同時專注於技術創新和營運韌性。優先投資於平台相容的純化技術，以減少單元操作的變異性並加速載體平台之間的製程轉移，同時擴展高解析度分析能力，從而實現快速的線上決策。加強與供應商的關係並對關鍵耗材進行多供應商認證，可減少對單一供應商的依賴，並在供應衝擊期間提高業務連續性。

採用穩健的混合方法調查方法，結合專家訪談、技術檢驗和二手文獻綜述，確保了基於證據的分析和透明的限制。

我們的研究方法結合了定性和定量研究，旨在建立一個全面、以證據為基礎的純化方法和市場動態觀點。主要研究包括對製程開發科學家、品質和法規專業人員、採購人員以及研發和生產機構的高階主管進行結構化訪談，以獲取有關技術應用、營運瓶頸和夥伴關係重點的第一手資訊。在條件允許的情況下，我們也透過現場考察和技術演示來補充這些訪談，以檢驗有關處理量、可重複性和易於實施性的說法。

策略整合重點闡述了實施綜合煉油策略、供應商韌性和分析方法如何有助於降低專案風險並加快開發進度。

這項分析表明，腺病毒純化正處於一個轉折點，技術選擇、區域趨勢和策略採購決策正在匯聚，共同決定專案的敏捷性和下游流程的成功。純化策略不再是後勤部門技術問題，而是影響臨床試驗時間、監管準備和生產成本結構的策略差異化因素。那些能夠將純化技術與特定應用需求相匹配、建立穩健的供應商網路並將高解析度分析融入流程控制的組織，將更有能力推進複雜的治療和疫苗項目。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 腺病毒純化試劑盒市場（依技術分類）

  • 層析法
    • 親和性和層析法
    • 離子交換層析法
    • 尺寸排阻層析法
  • 濾
    • 透析濾
    • 微濾
    • 超過濾
  • 降水法
    • 硫酸銨
    • PEG沉澱法

9. 腺病毒純化試劑盒市場（依規格分類）

  • 商業的
  • 研究所

第10章 腺病毒純化試劑盒市場（依等級分類）

  • 臨床應用
  • 用於研究

第11章 腺病毒純化試劑盒市場（依應用分類）

  • 基因治療
  • 研究
  • 疫苗生產

第12章 腺病毒純化試劑盒市場（依最終用戶分類）

  • 學術機構
  • 生物製藥公司
  • 契約製造組織
  • 受託研究機構

13. 各地區腺病毒純化試劑盒市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 腺病毒純化試劑盒市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國腺病毒純化試劑盒市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章美國腺病毒純化試劑盒市場

第17章：中國腺病毒純化試劑盒市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abcam PLC
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Lonza Group AG
  • Merck KGaA
  • Promega Corporation
  • Repligen Corporation
  • Sartorius AG
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi Biologics
Product Code: MRR-AE420CB153AF

The Adenovirus Purification Kit Market was valued at USD 1.23 billion in 2025 and is projected to grow to USD 1.34 billion in 2026, with a CAGR of 9.63%, reaching USD 2.34 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.23 billion
Estimated Year [2026] USD 1.34 billion
Forecast Year [2032] USD 2.34 billion
CAGR (%) 9.63%

A concise foundational overview of the technical, regulatory, and operational context driving adenovirus purification priorities across research and manufacturing environments

Adenovirus purification is a cornerstone process in modern gene delivery, vaccine development, and virology research, demanding rigorous control of purity, potency, and scalability. Recent advances in vector engineering, increased adoption of viral vectors in therapeutic pipelines, and heightened regulatory expectations have elevated purification as a cross-functional discipline that directly affects downstream efficacy and manufacturing economics. This report synthesizes technological developments, operational challenges, and stakeholder needs to provide a clear view of the strategic imperatives shaping purification strategies.

The introduction frames the technical and commercial context that influences procurement, process development, and capacity planning. It considers how laboratory practices, clinical-grade manufacturing requirements, and investigator-driven research use converge to create diverse performance criteria. By examining the interplay between chromatography, filtration, and precipitation approaches alongside application-specific demands such as gene therapy and vaccine production, the introduction sets the stage for deeper analysis of supply-chain resilience, regulatory alignment, and technology adoption trends.

How technological convergence, regulatory rigor, and platform strategies are reshaping adenovirus purification practice and commercial collaborations

The adenovirus purification landscape is undergoing transformative shifts driven by converging technological advancements, evolving regulatory expectations, and strategic shifts in developer priorities. Continuous process intensification, for example, is pushing teams to re-evaluate unit operations and integrate modular solutions that reduce hold times while preserving vector integrity. At the same time, the rise of automated and closed systems is reshaping how laboratories and manufacturing facilities balance throughput with contamination control, enabling smaller footprints to deliver consistently high-quality material.

Concurrently, materials science innovations are refining ligand chemistries and membrane performance, which together enhance selectivity and reduce non-specific adsorption. This is occurring as developers prioritize platform approaches that minimize re-development between vector variants. Regulatory agencies are also emphasizing robust impurity characterization and viral safety testing, prompting organizations to adopt orthogonal purification steps and invest in analytics that provide higher-resolution process understanding. As a result, partnerships between process developers, equipment suppliers, and service providers are becoming more strategic; firms align around shared roadmaps that accelerate time-to-clinic while managing technical risk.

Assessing the operational and strategic consequences of United States tariff measures introduced in 2025 on procurement, sourcing strategies, and manufacturing continuity

The introduction of tariffs on certain imported goods by the United States in 2025 has created a ripple effect across procurement, manufacturing planning, and global supply-chain architectures for bioprocessing inputs. Sourcing decisions for chromatography resins, membrane modules, and ancillary disposables have been reframed to account for changed landed costs and altered supplier economics. In response, many organizations have accelerated regional qualification of alternative vendors while increasing inventory buffers for critical items to prevent production interruptions.

These adjustments have also influenced capital expenditure timing for facilities that depend on imported specialized equipment. Procurement teams are increasingly evaluating total cost of ownership rather than upfront price alone, weighing factors such as installation lead times, local service capability, and spare-parts logistics. Trade policy shifts have further prompted manufacturers and contract partners to reassess multi-sourcing strategies, building redundancies into supplier networks and in some cases localizing critical inputs closer to production hubs. Ultimately, the tariff landscape has emphasized the need for cross-functional scenario planning that links procurement, supply-chain, and process development to maintain continuity and control operating margins.

Actionable segmentation analysis linking technology choices, application needs, end-user capabilities, scale considerations, and grade requirements to purification strategy and supplier selection

A nuanced understanding of segmentation is essential for tailoring purification approaches and commercial strategies across diverse user needs. From a technology perspective, chromatography remains central with distinct roles for affinity chromatography, ion exchange chromatography, and size exclusion chromatography, while filtration modalities such as diafiltration, microfiltration, and ultrafiltration serve complementary concentration and buffer-exchange functions. Precipitation techniques, including ammonium sulfate and PEG precipitation, continue to have niche applicability where simplicity and cost-efficiency are prioritized, particularly in early-stage or research-scale workflows. These technological distinctions impact decision criteria such as resolution, scalability, and compatibility with downstream analytics.

Application-driven segmentation highlights how gene therapy, research, and vaccine production impose different purity and regulatory thresholds, which in turn influence process architecture and supplier selection. End users vary in capabilities and priorities; academic institutes often prioritize flexibility and cost, biopharmaceutical companies emphasize regulatory alignment and scale, and contract manufacturing organizations together with contract research organizations balance throughput, reproducibility, and client-specific requirements. Scale considerations separate commercial from laboratory settings, informing choices around single-use versus stainless-steel equipment, process automation, and facility design. Finally, grade segmentation into clinical use and research use governs documentation, material traceability, and validation intensity, with clinical-grade workflows demanding more stringent controls and documentation practices. Interactions across these segmentation axes guide where investment in analytics, validation, and automation will deliver the greatest operational and strategic returns.

A regional framework that delineates how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics influence procurement choices, regulatory alignment, and capacity planning

Regional dynamics exert a profound influence on procurement, regulatory compliance, and capacity development across the adenovirus purification ecosystem. In the Americas, strong biopharmaceutical manufacturing clusters support extensive contract development and manufacturing activity, with localized supplier networks and service providers that enable rapid process transfer and scaling. This concentration facilitates collaborative development models, though it also concentrates demand for specific consumables and high-performance materials, which can stress supply chains during periods of elevated program activity.

Europe, Middle East & Africa presents a diverse regulatory and operational tapestry where national agencies and pan-regional frameworks intersect; firms prioritize harmonized documentation and cross-border quality systems to support multicountry trials and production. Localized manufacturing investments frequently emphasize compliance with stringent pharmacopoeial standards and the ability to support clinical-grade output. Asia-Pacific continues to expand capacity across both established and emerging hubs, combining cost-effective manufacturing with rapid infrastructure deployment. This region also supports a growing base of specialized suppliers and service providers, making it a focal point for both commercial-scale production and contract services. Across all regions, organizations are balancing considerations of regulatory alignment, supplier proximity, and resilience to geopolitical or trade disruptions when designing their purification and procurement strategies.

How technology differentiation, integrated service models, and strategic partnerships define competitive positioning and resilience among adenovirus purification suppliers

Competitive dynamics among companies operating in the adenovirus purification space are shaped by investments in differentiated technologies, vertical integration strategies, and service-based business models. Companies that focus on high-performance ligands and membrane innovations differentiate through product quality and process economics, while those emphasizing automation and closed-system platforms compete on ease of use and fit-for-purpose scalability. Service providers, including contract organizations and specialized process development groups, position themselves as extensions of client teams by offering integrated packages that combine development, scale-up, and transfer capabilities.

Strategic partnerships and licensing arrangements are increasingly common as technology developers seek routes to market while minimizing capital intensity. Similarly, companies that offer modular, application-specific solutions-such as pre-packed columns or single-use filtration assemblies tuned for viral vectors-gain traction by reducing validation burdens for end users. Intellectual property around novel ligands, membrane coatings, and process analytics is a differentiator, as is the ability to supply consistent, well-documented clinical-grade materials. Ultimately, the most resilient firms blend robust technical offerings with responsive supply-chain models and services that de-risk client programs from early development through commercialization.

Practical strategic and operational recommendations that balance innovation in purification technology with supply-chain resilience and regulatory preparedness for decision-makers

Industry leaders should adopt a dual focus on technological innovation and operational resilience to remain competitive and responsive to evolving client needs. Prioritize investments in platform-compatible purification technologies that reduce unit-operation variability and accelerate process transfer across vector platforms, while simultaneously expanding capabilities in high-resolution analytics that enable rapid in-process decision-making. Strengthening supplier relationships and qualifying multiple vendors for critical consumables will reduce single-source exposure and enhance continuity during supply shocks.

Operationally, leaders should implement scenario-based procurement plans that align inventory strategies with program risk profiles and production calendars. Embrace modular facility design and single-use technologies where appropriate to shorten campaign lead times and reduce capital risk. From a commercial perspective, offer differentiated service tiers, including bespoke development packages and technical training that lower barriers to adoption for smaller developers. Finally, invest in regulatory intelligence and cross-functional teams that can translate evolving guidance into validated processes, ensuring that clinical-grade material meets both scientific and compliance expectations.

A robust mixed-methods research methodology integrating expert interviews, technical validation, and secondary literature review to ensure evidence-based analysis and transparent limitations

The research approach combines qualitative and quantitative inquiry to construct a comprehensive, evidence-based perspective on purification practices and market dynamics. Primary research included structured interviews with process development scientists, quality and regulatory professionals, procurement leads, and executives from development and manufacturing organizations to capture firsthand insights on technology adoption, operational bottlenecks, and partnership preferences. These conversations were augmented with site visits and technical demonstrations where possible to validate claims around throughput, reproducibility, and ease of implementation.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance documents, technical white papers, and public disclosures to contextualize technological trends and regulatory expectations. Cross-validation steps included triangulating interview findings with product specifications, performance claims, and published comparative studies. Data integrity was further reinforced through expert panel reviews and sensitivity checks to identify potential bias or gaps. Limitations of the methodology are acknowledged, including variability in publicly available technical metrics and differences in reporting standards across organizations; however, the combined methodological rigor ensures that conclusions are grounded in multiple, independent information streams.

Strategic synthesis emphasizing how integrated purification strategy, supplier resilience, and analytics adoption collectively reduce program risk and accelerate development timelines

The analysis underscores that adenovirus purification is at an inflection point where technological choices, regional dynamics, and strategic sourcing decisions collectively determine program agility and downstream success. Purification strategy is no longer a back-office technical concern but a strategic differentiator that impacts time-to-clinic, regulatory readiness, and manufacturing cost structures. Organizations that align purification technology with application-specific requirements, qualify resilient supplier networks, and embed high-resolution analytics into process control will be better positioned to advance complex therapeutic and vaccine programs.

Looking ahead, collaboration across developers, equipment suppliers, and service providers will accelerate solutions that address both technical and commercial constraints. Adoption of platform approaches, coupled with investments in automation and validation-ready components, will continue to reduce friction during scale-up and transfer. Ultimately, stakeholders who proactively manage regulatory expectations, diversify sourcing, and prioritize process understanding will capture operational benefits and reduce program risk in a landscape that demands both speed and rigor.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Adenovirus Purification Kit Market, by Technology

  • 8.1. Chromatography
    • 8.1.1. Affinity Chromatography
    • 8.1.2. Ion Exchange Chromatography
    • 8.1.3. Size Exclusion Chromatography
  • 8.2. Filtration
    • 8.2.1. Diafiltration
    • 8.2.2. Microfiltration
    • 8.2.3. Ultrafiltration
  • 8.3. Precipitation
    • 8.3.1. Ammonium Sulfate
    • 8.3.2. Peg Precipitation

9. Adenovirus Purification Kit Market, by Scale

  • 9.1. Commercial
  • 9.2. Laboratory

10. Adenovirus Purification Kit Market, by Grade

  • 10.1. Clinical Use
  • 10.2. Research Use

11. Adenovirus Purification Kit Market, by Application

  • 11.1. Gene Therapy
  • 11.2. Research
  • 11.3. Vaccine Production

12. Adenovirus Purification Kit Market, by End User

  • 12.1. Academic Institutes
  • 12.2. Biopharmaceutical Companies
  • 12.3. Contract Manufacturing Organizations
  • 12.4. Contract Research Organizations

13. Adenovirus Purification Kit Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Adenovirus Purification Kit Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Adenovirus Purification Kit Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Adenovirus Purification Kit Market

17. China Adenovirus Purification Kit Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abcam PLC
  • 18.6. Bio-Rad Laboratories, Inc.
  • 18.7. Danaher Corporation
  • 18.8. Lonza Group AG
  • 18.9. Merck KGaA
  • 18.10. Promega Corporation
  • 18.11. Repligen Corporation
  • 18.12. Sartorius AG
  • 18.13. Takara Bio Inc.
  • 18.14. Thermo Fisher Scientific Inc.
  • 18.15. WuXi Biologics

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY DIAFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY DIAFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY DIAFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY MICROFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY MICROFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY MICROFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ULTRAFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ULTRAFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY AMMONIUM SULFATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY AMMONIUM SULFATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY AMMONIUM SULFATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PEG PRECIPITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PEG PRECIPITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PEG PRECIPITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CLINICAL USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CLINICAL USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CLINICAL USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY RESEARCH USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY RESEARCH USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY VACCINE PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY VACCINE PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 166. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 198. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 200. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 202. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)